About Company
- Legal Name: Autotelic Bio
- Registered country: Republic of Korea
- Address: Osongsaengmyeong 1-ro, Heungdeok-gu
- Number of employees: 25 - 49
Description:
Autotelic Bio researches and develops innovative new drugs with a vision of becoming a global leader in cancer treatment, driven to improve quality of life for patients with unmet medical needs. Founded in 2015 with board members bringing 15-20 years of experience across pharmaceutical business development, R&D and clinical study, the company's lead candidate ATB-301 (a TGF-β2-targeting antisense oligonucleotide combined with IL-2 therapy) is in Phase Ib trials, exploring TGF-β2 as a biomarker, suppression of IL-2 side effects in combination therapy, and the synergistic effects and safety of the combination approach.
Business Activities
ATC (Anatomical Therapeutic Chemical) Classification
Manufacturer
Key Products/Services
- :
- :
- :
Ratings
(0)
(0)
(0)
(0)
(0)
Comments
Filters:
Sort by:
No comments available.
Leave your rating & comment